Horizon Therapeutics
1 Horizon Way
Deerfield
IL
60015
United States
547 articles with Horizon Therapeutics
-
Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
10/21/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced additional data supporting the long-term efficacy of TEPEZZA for the treatment of TED.
-
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
10/13/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced results from a new analysis of the UPLIZNA pivotal Phase 2/3 N-MOmentum trial indicating a correlation between the depth of B-cell depletion and improved NMOSD patient outcomes.
-
New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
10/12/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new TEPEZZA data will be presented at the American Academy of Ophthalmology Annual Meeting (AAO 2021) in New Orleans and virtually, Nov. 12-15, 2021.
-
Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021
10/11/2021
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2021 financial results will be released on Wednesday, Nov. 3, 2021.
-
Horizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
10/6/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named one of the Top 100 Adoption-Friendly Workplaces in the United States by the Dave Thomas Foundation for Adoption for the third year in a row.
-
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2021
10/4/2021
Horizon Therapeutics plc Announces New UPLIZNA ® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2021
-
Jose Luis Casero Sanchez took advantage of his position in Goldman Sachs’ “control room” to gain insider knowledge of upcoming transactions, including those for several biopharma companies.
-
Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day
9/29/2021
Announcing Five Total New Development Programs for Daxdilimab (HZN-7734) and Dazodalibep (HZN-4920); Expect to Initiate New Phase 2 Trials in 2022, Bringing Total Development Programs to 27 --
-
Horizon was adding five new development programs for daxdilimab and dazodalibep. This brings the company’s pipeline to 27 development programs.
-
Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD)
9/23/2021
Horizon Therapeutics plc Announces Data Showing UPLIZNA ® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD)
-
Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021
9/23/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021.
-
Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Rare Disease Diagnosis
9/21/2021
Horizon Therapeutics plc is proud to announce two winning solutions of this year’s Horizon Prize, ThinkGenetic Inc. and Congenica.
-
Clinical Catch-Up: September 6-10
9/13/2021
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look. -
Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)
9/7/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 4 clinical trial evaluating the efficacy and safety of TEPEZZA for the treatment of chronic (inactive) TED.
-
Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
8/4/2021
Record Second-Quarter 2021 Net Sales of $832.5 Million Increased 80 Percent; Second-Quarter 2021 GAAP Net Income of $158.1 Million; Adjusted EBITDA of $366.9 Million.
-
Fortune Names Horizon Therapeutics One of the 2021 Best Workplaces for Millennials™
7/16/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the 2021 Fortune Best Workplaces for Millennials™ list for the second consecutive year. Horizon ranked 16th out of 100 large companies.
-
Horizon Therapeutics plc to Release Second-Quarter 2021 Financial Results and Host Webcast on Aug. 4, 2021
7/8/2021
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2021 financial results will be released on Wednesday, Aug. 4, 2021.
-
BioSpace Movers & Shakers, July 2
7/2/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Horizon Therapeutics plc to Host Virtual R&D Day on Sept. 29, 2021
6/30/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it will host a virtual R&D Day for investors and analysts on Wednesday, Sept. 29, 2021 at 8 a.m. CT.
-
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus
6/29/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 trial to evaluate its development-stage medicine HZN-7734.